Latest stories on GILD
Midday Pulse: S&P 500 top intraday gainers
Seeking Alpha62 · neutralgeneral
3 Big Pharma Earnings Reports to Watch: Eli Lilly, Merck and Gilead
24/7 Wall St.42 · neutralearnings
What iShares Biotechnology ETF (IBB) Bought: Gilead Leads on Monday
GuruFocus56 · neutralgeneral
ETFs Are Net Sellers of Gilead Sciences (GILD) on Oct. 23
GuruFocus42 · neutralgeneral
Lilly and Gilead stand out ahead of healthcare earnings, says Citi's Geoff Meacham
CNBC63 · neutralanalyst
Amgen vs. Gilead Sciences: Which Biotech Dividend Stock Is the Better Buy?
The Motley Fool55 · neutralanalyst
Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week
Stocktwits News63 · neutralm&a
Gilead’s Weekly HIV Pill Study Adds Long-Acting Firepower to GILD’s Pipeline
TipRanks63 · neutralproduct/pr
Jefferies raises Gilead stock price target to $185 on acquisition
Investing.com Analyst Ratings67 · bullishanalyst
Gilead Acquires Oral IL-23R Inhibitor Program for $1.275 Billion in Cash
Morningstar64 · neutralm&a
BioNTech to investigate pumitamig in combination with Gilead's Trodelvy
Seeking Alpha64 · neutralproduct/pr
Gilead Acquires Oral IL-23R Inhibitor Program for $1.275B in Cash
MarketWatch64 · neutralm&a
Gilead acquires oral IL-23R inhibitor program from PepStar for ~$1.3B
Seeking Alpha64 · neutralm&a
Gilead Sciences Inc. stock underperforms Thursday when compared to competitors despite daily gains
MarketWatch42 · neutralgeneral
Gilead to acquire IL-23R inhibitor program from PepStar Therapeutics
The Fly64 · neutralm&a
Gilead to buy PepStar’s inflammation drug program in $1.28 billion deal
Investing.com Markets64 · neutralm&a
Texas AG secures $45M settlement with Gilead
The Fly58 · neutralgeneral
Gilead Sciences stock may move 4.6% on Oct. 29 earnings release
Investing.com Markets50 · neutralearnings
Gilead to present new clinical, real-world evidence across PBC, HDV
The Fly58 · neutralproduct/pr
BioNTech and Gilead Recast Phase 3 ROSETTA Trial Around ADC Combo in Triple-Negative Breast Cancer
TipRanks63 · neutralproduct/pr
Gilead to Present New Data on Treatment Response and Long-Term Management of Rare Liver Diseases at The Liver Meeting® 2026
StockTitan56 · neutralproduct/pr
BioNTech announces collaboration, supply agreement with Gilead
The Fly64 · neutralproduct/pr